Cancer Biology & Medicine

Cancer Biology & Medicine is a peer-reviewed open-access oncology journal sponsored by the China Anti-Cancer Association together with Tianjin Medical University Cancer Institute and Hospital, published monthly under its current title since 2012, with a 2025 Journal Impact Factor of 12.4（Cancer Biology & Medicine）是由（China Anti-Cancer Association）与（Tianjin Medical University Cancer Institute and Hospital）共同主办的同行评审开放获取肿瘤学期刊，自 2012 年起以现刊名按月出版，2025 年影响因子为 12.4。

Scope

• Its scope covers cancer genetics together with cancer and stem cell biology其涵盖范围包括肿瘤遗传学以及肿瘤与干细胞生物学。
• It covers molecular and clinical immunology涵盖分子免疫学与临床免疫学。
• Topics include cancer prevention and epidemiology and cancer biomarkers议题包括肿瘤预防与流行病学以及肿瘤生物标志物。^[1]
• It covers radiation oncology and oncology clinical trials涵盖放射肿瘤学与肿瘤临床试验。
• It addresses mechanisms of drug sensitivity and resistance关注药物敏感性与耐药机制。
• It covers targeted therapy and immunotherapy涵盖靶向治疗与免疫治疗。^[2]
• It also covers multidisciplinary treatment and personalized medicine还涵盖多学科治疗与个体化医疗。
• It publishes perspectives on cancer types prevalent in China该刊发表针对中国高发肿瘤类型的观点文章。^[3]

History

• The journal originated in 2004 as the English edition of Chinese Journal of Clinical Oncology founded by Xishan Hao该刊源于 2004 年由郝希山创办的《中国肿瘤临床》英文版。
• It was renamed Clinical Oncology and Cancer Research and adopted the current title Cancer Biology & Medicine in 2012该刊更名为（Clinical Oncology and Cancer Research），并于 2012 年启用现刊名（Cancer Biology & Medicine）。
• It is co-sponsored by the China Anti-Cancer Association and Tianjin Medical University Cancer Institute and Hospital该刊由（China Anti-Cancer Association）与（Tianjin Medical University Cancer Institute and Hospital）共同主办。
• It is a fully open-access monthly with all full texts freely available worldwide该刊为完全开放获取月刊，全部全文面向全球免费可见。
• It is indexed in SCIE, MEDLINE, PubMed and PubMed Central and Scopus该刊被（SCIE）、（MEDLINE）、（PubMed）与（PubMed Central）以及（Scopus）收录。
• It received its first Journal Impact Factor of 4.607 in 2017 and reached 8.4 in 2024 and 12.4 in 2025该刊 2017 年获得首个影响因子 4.607，2024 年为 8.4，2025 年为 12.4。

Editors

• Its editor-in-chief is Xishan Hao of Tianjin Medical University Cancer Institute and Hospital其主编为郝希山，任职于（Tianjin Medical University Cancer Institute and Hospital）。
• Its executive editor-in-chief is Jihui Hao of the same institute其执行主编为郝继辉，同属该院。
• Its deputy editors-in-chief are Ning Zhang of Peking University Health Science Center and Guoguang Ying其副主编为张宁（北京大学医学部）与应国光。
• Its associate editors include Chengchao Shou, Eduardo L. Franco and Emad El-Omar其副编辑包括（Chengchao Shou）、（Eduardo L. Franco）与（Emad El-Omar）。
• They also include Hongbing Shen, Jia Fan and Lin Shen还包括（Hongbing Shen）、（Jia Fan）与（Lin Shen）。
• Its consultants include Bruce E. Johnson, Dongxin Lin, Franco Cavalli and Webster Cavenee其顾问包括（Bruce E. Johnson）、（Dongxin Lin）、（Franco Cavalli）与（Webster Cavenee）。
• The founding editorial board drew 116 scholars from 29 countries and regions创刊编委会汇集了来自 29 个国家和地区的 116 位学者。